A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Exclusion Criteria

• •1. Patients who have a contraindication to DUPIXENT® according to the USPI
• •2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
• •3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)